ORIC Pharmaceuticals, Inc.
General ticker "ORIC" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $847.0M (TTM average)
ORIC Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 1.6%.
Estimated limits based on current volatility of 4.5%: low 7.69$, high 8.47$
Factors to consider:
- Total employees count: 115 as of 2024
- Top business risk factors: Operational and conduct risks, Economic downturns and volatility, Dependence on product success, Regulatory and compliance, Labor/talent shortage/retention
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [6.08$, 13.27$]
- 2026-12-31 to 2027-12-31 estimated range: [5.88$, 12.89$]
Financial Metrics affecting the ORIC estimates:
- Negative: with PPE of -5.4 at the end of fiscal year the price was high
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Inventory ratio change, % of 0 <= 0
- Negative: negative Net income
- Positive: Shareholder equity ratio, % of 94.00 > 64.29
Short-term ORIC quotes
Long-term ORIC plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $110.78MM | $142.90MM | $143.00MM |
| Operating Income | $-110.78MM | $-142.90MM | $-143.00MM |
| Non-Operating Income | $10.08MM | $15.05MM | $13.54MM |
| R&D Expense | $85.17MM | $114.07MM | $109.82MM |
| Income(Loss) | $-100.70MM | $-127.85MM | $-129.47MM |
| Net Income(Loss)* | $-100.70MM | $-127.85MM | $-129.47MM |
| Stockholders Equity | $224.09MM | $243.12MM | $384.36MM |
| Assets | $252.01MM | $274.14MM | $408.89MM |
| Operating Cash Flow | $-85.69MM | $-112.66MM | $-110.97MM |
| Capital expenditure | $0.85MM | $1.19MM | $0.71MM |
| Investing Cash Flow | $-43.40MM | $22.14MM | $-148.03MM |
| Financing Cash Flow | $85.66MM | $126.55MM | $245.26MM |
| Earnings Per Share** | $-1.96 | $-1.83 | $-1.47 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.